Evidence map›Paper›PMID 40178767›Full record

ReviewJournal of neuro-oncology2025

Molecular testing and targeting for solid tumors with CNS metastases.

Kate E Therkelsen, Toni Cao, Meaghan Roy-O'Reilly, Brian Stocksdale, Seema Nagpal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kate E TherkelsenDivision of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Toni CaoDivision of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Meaghan Roy-O'ReillyDivision of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Brian StocksdaleDivision of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Seema NagpalDivision of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA. snagpal@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The landscape of molecular testing in solid tumors is rapidly expanding. Understanding testing options and limitations can inform treatment decisions for many patients with metastatic disease to the central nervous system (CNS).

Indexed as

Biomarkers, TumorCentral Nervous System NeoplasmsMolecular Targeted TherapyNeoplasmsHumansBiomarkers, TumorBrain metastasesBreast cancerChemotherapyLung cancerMelanomaMetastatic cancerMolecular testingTargeted treatment

Identifiers

PMID40178767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.